
## John R Schmelzer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11396819/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CYP4F2 genetic variant alters required warfarin dose. Blood, 2008, 111, 4106-4112.	1.4	471
2	Evaluation of Genetic Factors for Warfarin Dose Prediction. Clinical Medicine and Research, 2007, 5, 8-16.	0.8	138
3	A randomized controlled trial of genotype-based Coumadin initiation. Genetics in Medicine, 2011, 13, 509-518.	2.4	112
4	Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism. Medical Care, 2017, 55, e137-e143.	2.4	97
5	Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study. Thrombosis Research, 2020, 189, 112-118.	1.7	15
6	Treatment and Outcomes of Acute Pulmonary Embolism and Deep Venous Thrombosis: The CVRN VTE Study. American Journal of Medicine, 2019, 132, 1450-1457.e1.	1.5	12
7	Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses. Clinical Medicine and Research, 2011, 9, 119-124.	0.8	9
8	Agricultural Injury Prevention: The Need for Greater Cooperation and Involvement. Journal of Rural Health, 1990, 6, 221-230.	2.9	4
9	Reinitiating Warfarin: Relationships Between Dose and Selected Patient, Clinical and Hospital Measures. Clinical Medicine and Research, 2015, 13, 1-6.	0.8	2